ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion
Agendia and Roche evaluate BluePrint’s stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 10, 2020 – Agendia, Inc., a world leader in precision oncology Read More
Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020
Agendia shares subgroup analyses from the first of its kind, national FLEX Registry with complete, clinically-annotated full genome expression profiling IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2020 – Agendia, Inc., a world Read More
FOCUS Study Shows MammaPrint Accurately Identifies Extremely Indolent Cancers
Findings confirm subanalysis of STO-3 trial and provide foundation for consideration of de-escalation of treatment in post-menopausal patients guided by genomic testing IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2020 – Agendia, Inc., Read More
Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer
Co-development program will utilize next-generation digital pathology platform and AI-based technology to provide real-time genomic testing results Partnership to create new products enabling faster access to predictive information in treatment planning for patients with breast Read More